Related Experiment Video

Updated: Jul 5, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Protein kinase A effects of an expressed PRKAR1A mutation associated with aggressive tumors

Elise Meoli1, Ioannis Bossis, Laure Cazabat

  • 1Section on Endocrinology and Genetics, Program in Developmental Endocrinology and Genetics, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland 20892, USA.

Cancer Research
|May 3, 2008
PubMed

Insights

A PRKAR1A mutation causes increased protein kinase A (PKA) activity by reducing the mutant R1 alpha subunit's binding to the catalytic subunit. This suggests PKA hyperactivity, not altered subunit levels, drives tumorigenesis.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Tumorigenic mutations in PRKAR1A often result in mRNA decay.
  • Tumor formation is linked to elevated type II protein kinase A (PKA) subunits.
  • A specific mutation, IVS6+1G>T, creates a truncated R1 alpha protein (R1 alpha Delta 6).

Purpose of the Study:

  • To compare the in vitro properties of wild-type (wt) R1 alpha and the mutant R1 alpha Delta 6.
  • To investigate the impact of R1 alpha Delta 6 on PKA activity, subunit localization, and interactions.

Main Methods:

  • In vitro comparison of wt-R1 alpha and R1 alpha Delta 6.
  • Assessment of PKA activity, subunit expression, and target molecule phosphorylation.
  • Confocal microscopy to observe R1 alpha-GFP and C alpha-Cerulean interactions.

Main Results:

  • R1 alpha Delta 6 expression caused aberrant cell morphology and increased PKA activity.
  • No increase in type II PKA subunits was observed with R1 alpha Delta 6.
  • Mutant R1 alpha showed reduced binding to the catalytic subunit (C alpha) and decreased nuclear C alpha localization.

Conclusions:

  • The R1 alpha Delta 6 mutation increases PKA activity due to decreased binding to C alpha.
  • This mechanism of increased kinase activity and potential tumorigenesis does not require changes in other PKA subunits.
  • A shift to type II PKA activity is not essential for increased kinase activity or tumor development.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...